(lp0
S"Here's Why ImmunoGen, Inc. Skyrocketed 45% in February Motley Fool - Mar 9, 2017 Shares of ImmunoGen , a small-cap biopharmaceutical company that utilizes its proprietary antibody-drug conjugate  technology to fight various forms of cancer, skyrocketed 45% during February, according to data from S&amp;P Global&nbsp;...The 4.5% Stake of ImmunoGen, Inc.  Owned by Primecap Management Company - DailyQuintImmunoGen, Inc.  Cut to Hold at Zacks Investment Research - BBNS"
p1
aS"Why ImmunoGen, Inc. Skyrocketed Higher Today Motley Fool - Feb 27, 2017 It's also possible investors are buying ahead of the Society of Gynecologic Oncology's Annual Meeting of Women's Cancer next month where ImmunoGen is scheduled to present additional phase 1 data from a subset of patients getting its cancer medication&nbsp;...ImmunoGen Inc  Has A Wave Of Catalysts About To Hit Press - Insider FinancialImmunoGen, Inc.  Update On Trial of Mirvetuximab Soravtansine - Journal Transcript"
p2
aS"Today's Brokerage Rating: ImmunoGen, Inc. , La Quinta Holdings Inc.  StockNewsJournal - 15 hours ago Investors who are keeping close eye on the stock of ImmunoGen, Inc.  established that the company was able to keep return on investment at -89.37 in the trailing twelve month while Reuters data showed that industry's average stands at&nbsp;..."
p3
aS"3 Charts That Show the Potential Risks and Rewards for Immunogen, Inc. Stock Motley Fool - Mar 4, 2017 After 36 years of being in business, Immunogen  has yet to make a profit. Unfortunately, the biotech still isn't close to reaching break-even status."
p4
aS'Eye on Technicals for ImmunoGen Inc  Baxter Review - 8 hours ago When applying indicators for technical analysis, traders and investors might want to examine the ATR or Average True Range. The current 14-day ATR for ImmunoGen Inc  is currently sitting at 0.25. The ATR basically measures the volatility of a ...'
p5
aS'Mirva had only benchmark trial results in broad population platinum resistant ... Seeking Alpha - Mar 20, 2017 Immunogen  is a nanocap clinical stage biopharma developing Mirventuximab soravtansine, an antibody-drug conjugate  with a monoclonal antibody  that binds to FRalpha-positive tumor cells thereby delivering&nbsp;...'
p6
aS'Immunogen Inc.  PT Lowered to $1.30 at Morgan Stanley StreetInsider.com - Mar 1, 2017 Morgan Stanley lowered its price target on Immunogen Inc.  to $1.30  while maintaining a Underweight rating.'
p7
aS'ImmunoGen Inc.  Moves Higher on Volume Spike for March 10 Equities.com - Mar 10, 2017 ImmunoGen Inc.  traded on unusually high volume on Mar. 10, as the stock gained 1.91% to close at $3.73. On the day, ImmunoGen Inc. saw 4.78 million shares trade hands on 14,569 trades. Considering that the stock averages only a daily volume of&nbsp;...Stock Showing Surging Activity: ImmunoGen, Inc.  - HugoPress'
p8
aS'ImmunoGen, Inc. , Summit Materials, Inc.  Stock Eyes Ahead of Earnings The USA Commerce - Mar 21, 2017 Presently ImmunoGen, Inc.  stock have an ABR of 2.61. This is built on a simplified 1 to 5 scale where 1 represents a Strong Buy and 5 a Strong Sell.'
p9
aS'ImmunoGen Inc.  Soars 6.08% on March 02 Equities.com - Mar 2, 2017 ImmunoGen Inc.  had a good day on the market for Thursday March 02 as shares jumped 6.08% to close at $3.58. About 5.06 million shares traded hands on 17,783 trades for the day, compared with an average daily volume of 1.9 million shares out of&nbsp;...'
p10
a.